Effect of antiª²platelet drug in unstable angina pectoris undergoing percutaneous coronary angioplasty

    CHENG Ruª²Feng£¬ WANG Haiª²Chang, CHENG Heª²Xiang

    Department of Cardiovasology, Xijing Hospital, Fourth Military University, Xi¡¯an 710033, China

    ¡¾Abstract¡¿ AIM: To compare the effects of aspirin and clopidogrel on platelets between patients with unstable angina pectoris of type A and those with unstable angina pectoris of type B coronary lesions, who all had received coronary stenting. METHODS: According to ACC/AHA classification, type A lesion unstable angina pectoris patients (group A, n=32) and type B lesions unstable angina pectoris patients (group B, n=30) were included in the study. All the patients underwent percutenous transluminal coronary angioplasty and coronary stenting. They took clopidogrel loading dosage 300 mg and aspirin 300 mg no less than 2 h preª²operation and post operation 75 mg clopidogrel and 300 mg aspirin daily. Peripheral venous blood was collected before, 2 h after taking the medicine, and 6 h, 24 h and one month after angioplasty, and plasma samples were analyzed for TXB2, GMP140 and MPAR by enzyme linked immunoadsorbent assay (ELISA) and immune turbidimetry respectively. RESULTS: ¢Ù At 2 h after taking medicine, the levels of the above indexes in group A and group B were significantly lower than those before taking medicine. ¢Ú At 6 h and 24 h after angioplasty, the levels of above the three indexes in both groups were significantly higher than those before and 2 h after taking medicine. No significant difference was found at 2 h after taking medicine and at one month after angioplasty. But in group B, the levels of TXB2 and GMP140 were still significantly higher than those at 2 h after taking medicine. ¢Û Before and 2 h after taking medicine, at 6 h, 24 h and one month after angioplasty, the levels of the above indexes in group B were significantly higher than those in group A except for MPAR at 2 h after taking medicine. CONCLUSION: Routine antiplatelet therapy can effectively inhibit platelet activation in unstable angina pectoris patients with type A coronary lesions, but is not very effective in type B coronary lesion patients. ......